Everything you need to win Superluminal Medicines — in one platform.
Who to reach, what to say, and why now on Superluminal Medicines — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Superluminal Medicines — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Superluminal Medicines Secures $120 Million Series A Round for Clinical Development and Expansion of Small Molecule Pipeline
Sep 09, 2024•almost 2 years ago
Contract Type
partnership
BostonBiotechnologyHealth Care
Description
Superluminal Medicines, Inc. has announced the closing of a $120 million Series A funding round led by RA Capital Management, with participation from existing investors and new investors such as Catalio Capital Management, Eli Lilly and Company, and Cooley LLP. The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets.
Company Information
Company
Superluminal Medicines
Location
Boston, Massachusetts, United States
About
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
BostonBiotechnologyHealth Care